|
Bugs vs. Drugs: The Pharmacist’s Challenge Podcast CE Activity 1
|
|
Episode 1-3
- Gram-negative Bacteria Issue 1
- Gram-negative Bacteria Issue 2
- Gram-negative Bacteria Issue 3
|
Episode 4-6
- Gram-positive Bacteria Issue 1
- Gram-positive Bacteria Issue 2
- Gram-positive Bacteria Issue 3
|
Program Overviews
In Episodes 1–3, Dr. David Burgess and Dr. David Nicolau discuss the clinical challenges of
effectively treating resistant and multidrug-resistant gram-negative bacterial infections.
In Episodes 4–6, Dr. Robert Rapp and Dr. David Nicolau discuss the challenges related to
the growing prevalence of methicillin-resistant Staphylococcus aureus in both the hospital
and the community.
|
Learning Objectives
- Discuss the clinical consequences of antimicrobial-resistant gram-negative bacterial infections
- Recognize the increasing prevalence of multidrug-resistant gram-negative bacilli in hospitals
- Realize the threat caused by multidrug-resistant Acinetobacter baumannii infections
- Discuss the resistance development in Staphylococcus aureus
- Differentiate between the types of infections associated with hospital-acquired MRSA and community-aquired MRSA
- Recognize the clinical consequences of MRSA strains with high vancomycin MIC
|
Accreditation
Center for Independent Healthcare Education (the Center) is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education. The Center designates 1.75 contact
hour(s) (0.175 CEUs) of continuing pharmacy education credit to this activity.
ACPE Universal Program Number: 473-999-08-002-H01-P.
To receive a CE Statement of Credit, review all relevant activity information, listen to all six
audio files, and return a completed CE post-test and evaluation form. Documentation of credit will
be mailed 6-8 weeks after receipt of materials.
|
Release Date: March 18, 2008
Expiration Date: April 21, 2009
Time to complete activity: 1.75 hours
|
Off-label Disclosure Statements
In episodes 1, 2, and 5, non-FDA approved and investigational use of agents is not discussed.
In episode 3, investigational use of colistin for the treatment of Acinetobacter baumannii infections is
discussed. Please refer to the prescribing information of colistin for FDA-approved
indications, contraindications, and warnings.
In episode 4, investigational use of the following non-FDA approved agents (as of January 25, 2008) is
discussed: ceftaroline, ceftobiprole, dalbavancin, oritavancin, and telavancin for the treatment of
MRSA infections.
In episode 6, investigational use of doxycycline for the treatment of MRSA infections is
discussed. Please refer to the prescribing information of doxycycline for FDA-approved
indications, contraindications, and warnings.
|
Recommended Readings
For additional references for this activity, please click on “Recommended Readings” in the left panel.
|
Listen, Learn, and Earn
Listen to an episode by clicking on it in the left panel. CE forms for this activity are now available
by clicking on “CE Forms” in the left panel.
|
|